Advertisement Covers CROI 2017


Substantial Statin Treatment Gap Exists for People Living With HIV

May 9, 2017

Higher rates of cardiovascular disease (CVD) are well documented in people with HIV infection especially as they age, and using statin treatments with HIV regimens is generally safe and effective. However, in a presentation from a 12-year analysis of the large NA-ACCORD cohort at the 2017 Conference on Retroviruses and Opportunistic Infections, more than half of those who could use a statin to treat their CVD had not received a prescription for it.

Researchers looked at the medical records of more 86,000 people from Jan 2001 to Dec 2013. They used the ATP III Guidelines to assess whether a person was eligible to receive a statin prescription based upon various risk factors such as low and high density cholesterol, triglycerides, Framingham score, diabetes, CD4 counts, viral loads, AIDS diagnosis, age and smoking history. They included those individuals with no prescription at or within 6 months of the indication for a statin prescription.

From their analysis, a large treatment gap had emerged from all of those who were eligible for getting a prescription: between those who had received one (12%) and those who hadn't (88%). The good news is that the rate of statin prescriptions had increased 300% (6% to 18%) over time while the statin treatment gap had declined (73% to 53%). However, still more than 50% of those who could have been prescribed a statin had not received one throughout the 12 years of study.

Those who were less likely to get a statin despite possible benefits from using one were younger people (<40 years), African Americans, current smokers, those with low CD4 counts (<200) and those on a protease inhibitor regimen. Factors that increased the likelihood that a prescription was written included older age (>50 years), being white, MSM, without hepatitis C, higher CD4 counts and undetectable viral load.

These results point to the need for more attention during medical visits to assessing and using documented risk factors for guiding the prescription of statins in those who could benefit from using them.


KN Althoff, et al. The Large Gap Between Statin Eligibility and Prescription Among HIV+ in North America. 2017 CROI, Seattle. Abstract 619.

Related Stories

Less Than Half of People With HIV Who Are Eligible for Statins Receive Them
Rosuvastatin for Chronic Obstructive Pulmonary Disease (COPD) in People With HIV
This Week in HIV Research: Reducing Cardiovascular Risk; and Monitoring Renal Function With PrEP

This article was provided by Project Inform. It is a part of the publication The 24th Conference on Retroviruses and Opportunistic Infections. Visit Project Inform's website to find out more about their activities, publications and services.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.